• Journal of Labour Economics
• /
• v.38 no.1
• /
• pp.67-92
• /
• 2015

This paper empirically analyses the effect of labor union on firm's profit rate in Korea. For this purpose a panel data set has been constructed for the period of 1990-2009 using "TS2000", and the data set has been subdivided into two: one is the 'non-variant group' in which firm's union status has not changed, and the other is 'variant group' in which firm's union status has changed from non-union to union during the sample period. It has been found that for 'non-variant group' there is no significant union effect on profit rate. However, for 'variant group' the presence of union has been found to decrease firm' profit rate in terms of return on equity.

• Proceedings of the Technology Innovation Conference
• /
• 2005.02a
• /
• pp.22-41
• /
• 2005

본 연구에서는 기업의 기술혁신활동 결정요인을 과학기술정책연구원이 발표한 KIS(Korean Innovation Survey) 2002를 활용하여 분석하였다. 특히 혁신활동에 있어서 기업규모와 네트워크의 역할에 초점을 맞추었다. 기술혁신활동을 제품혁신, 제품개선, 그리고 공정혁신으로 구분하였으며, 기술혁신활동의 결정요인으로 이윤율, 수출비율, 해외지분, 기업연령, 시장집중도, R&D활동 착수여부, 그리고 산업별 R&D집약도 등이 추가로 고려되었다. 분석된 표본은 제조업에 속한 1,124개 기업으로 정성적 분석방법인 로지스틱 회귀모형(logistic regression)을 사용하였다. 분석결과, 첫째 기업의 기술혁신활동 결정요인은 혁신유형에 따라서 다르게 분석되었다. 예를 들어, 기업규모와 기술혁신활동에 관한 슘페터 가설은 제품혁신에서는 성립하지 않는 것으로 나타났으나. 제품개선 및 공정혁신에 대해서는 성립하는 것으로 분석되었다. 둘째, 예측한 대로 소기업과 대기업간 기술혁신활동의 결정요인에 있어서 많은 차이점이 발견되었고, 이러한 차이는 제품혁신과 공정혁신에서 현격하게 나타났다. 셋째, 기업규모 및 혁신유형에 관계없이 외부적 네트워크는 기술혁신활동에 대해 정(正)(+)의 유의한 효과를 나타내어, 혁신활동에서 협력의 중요성을 확인해 주었다. 그러나 협력대상별 네트워크효과는 기업규모와 혁신유형에 따라서 많은 차이점을 보여주었다.

• Journal of Korea Technology Innovation Society
• /
• v.10 no.3
• /
• pp.406-430
• /
• 2007

Most pharmaceutical licensing deals are made in the early stage of drug development. While this development process is not unique for complicated technology, a special feature of drug development is that it is highly regulated and a well-defined process. Its statistics in terms of costs and chances of technical success have been researched extensively. This enables relatively detailed calculations as benchmarks for actual deals to be made. Based on such calculations and on the analysis of licensing terms in published agreements, various companies offer quite expensive information, databases, software programs and consultation services to help establish what might be reasonable economic terms in a licensing deal. Over the years, pharmaceutical royalties have been the subject of various articles in journals. Most specific on this subject was the article on determining pharmaceutical royalties. Many other articles are about a more general nature deal with determining reasonable royalty rates, evaluating and underpinning the empirical value and usefulness of the 25% rule. The object of this article is to provide a relatively simple analytical approach based on the major economic terms underlying pharmaceutical licensing deals. The aim is to enhance the understanding of the relations between the major factors involved. Details are disregarded, as generally, where the terms of licensing deals depend on predictions over a considerable length of time, the value of detail is limited. Some specific issues addressed by the approach are the impact on profits of large investments, high risks and long development times characteristic of drug development, the consequent strong impact that the ultimate sales levels and operating margins may have on what might be considered a reasonable royalty rate, and the relationship between upfront payments and milestone payments to be paid during pharmaceutical development and the royalties due once the drug enters the market.